Condition: BRAF V600E Mutation · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.
This description comes directly from the study's public registry record.
Study Chair, MD · 410-955-8837 · ksolt1@jhmi.edu
Principal Investigator, MD · 410-955-8837
Always discuss trial participation with your own doctor first.
| Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06610682